The Sound Of Science - Otonomy Tinnitus Talk podcast

Artwork

Tinnitus Hub Science Fitness Biology Medicine

Innhold levert av Tinnitus Hub. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Tinnitus Hub eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Tinnitus Talk « »
The Sound of Science - Otonomy

3+ y ago 1:36:26

Del

MP3•Episoder hjem

Innhold levert av Tinnitus Hub. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Tinnitus Hub eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Very few commercial drug companies focus on hearing disorders. Even fewer focus on tinnitus. Otonomy does both. In this exclusive interview, we took a deep dive with Otonomy’s executives into their drug pipeline.

We spoke to David Weber (PhD), President and CEO, and Alan Foster (PhD), Chief Scientific Officer. They shared their views on what they see as the “renaissance” of hearing research and how there is currently more investor appetite to address hearing issues. We discussed why Otonomy is not only seeking solutions for different kinds of hearing loss, but also tinnitus specifically.

The interview covers each of the company’s drugs in-depth, from its mechanism of action to commercialization plans. Tinnitus drug OTO-313 targets overexcitation of the auditory nerve, which is theorized to cause tinnitus. Which types of tinnitus will benefit remains an open question, but the tinnitus community will no doubt follow the drug’s future with keen interest.

Become a Tinnitus Talk Podcast Patron at https://moretinnitustalk.com for bonus content, video interviews, Ask an Expert series, and more!

… continue reading

25 episoder

#Tinnitus Hub #Science #Fitness #Biology #Medicine

Artwork

The Sound of Science - Otonomy

39 subscribers

published 3+ y ago

Del

MP3•Episoder hjem

Innhold levert av Tinnitus Hub. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Tinnitus Hub eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Very few commercial drug companies focus on hearing disorders. Even fewer focus on tinnitus. Otonomy does both. In this exclusive interview, we took a deep dive with Otonomy’s executives into their drug pipeline.

We spoke to David Weber (PhD), President and CEO, and Alan Foster (PhD), Chief Scientific Officer. They shared their views on what they see as the “renaissance” of hearing research and how there is currently more investor appetite to address hearing issues. We discussed why Otonomy is not only seeking solutions for different kinds of hearing loss, but also tinnitus specifically.

The interview covers each of the company’s drugs in-depth, from its mechanism of action to commercialization plans. Tinnitus drug OTO-313 targets overexcitation of the auditory nerve, which is theorized to cause tinnitus. Which types of tinnitus will benefit remains an open question, but the tinnitus community will no doubt follow the drug’s future with keen interest.

Become a Tinnitus Talk Podcast Patron at https://moretinnitustalk.com for bonus content, video interviews, Ask an Expert series, and more!

… continue reading

25 episoder

#Tinnitus Hub #Science #Fitness #Biology #Medicine

Alle episoder

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema

Lytt til dette showet mens du utforsker